
Omnicell (OMCL) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
290.6M
Gross Profit
127.7M
43.94%
Operating Income
8.1M
2.79%
Net Income
5.6M
1.94%
EPS (Diluted)
$0.12
Balance Sheet Metrics
Total Assets
2.2B
Total Liabilities
894.4M
Shareholders Equity
1.3B
Debt to Equity
0.71
Cash Flow Metrics
Operating Cash Flow
28.3M
Free Cash Flow
10.2M
Revenue & Profitability Trend
Omnicell Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.1B | 1.1B | 1.3B | 1.1B | 892.2M |
Cost of Goods Sold | 641.2M | 650.3M | 707.0M | 577.4M | 478.9M |
Gross Profit | 471.0M | 496.8M | 589.0M | 554.7M | 413.3M |
Gross Margin % | 42.3% | 43.3% | 45.4% | 49.0% | 46.3% |
Operating Expenses | |||||
Research & Development | 90.4M | 97.1M | 105.0M | 75.7M | 70.2M |
Selling, General & Administrative | 380.3M | 434.6M | 486.3M | 389.4M | 307.6M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 470.7M | 531.7M | 591.3M | 465.1M | 377.8M |
Operating Income | 337.0K | -34.9M | -2.3M | 89.5M | 35.5M |
Operating Margin % | 0.0% | -3.0% | -0.2% | 7.9% | 4.0% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 25.6M | -20.1M | -2.5M | 66.0M | 29.3M |
Income Tax | 13.1M | 263.0K | -8.1M | -11.8M | -2.8M |
Effective Tax Rate % | 51.0% | 0.0% | 0.0% | -17.9% | -9.7% |
Net Income | 12.5M | -20.4M | 5.6M | 77.8M | 32.2M |
Net Margin % | 1.1% | -1.8% | 0.4% | 6.9% | 3.6% |
Key Metrics | |||||
EBITDA | 90.1M | 60.7M | 96.8M | 174.4M | 107.1M |
EPS (Basic) | $0.27 | $-0.45 | $0.13 | $1.79 | $0.76 |
EPS (Diluted) | $0.27 | $-0.45 | $0.12 | $1.62 | $0.74 |
Basic Shares Outstanding | 46047000 | 45212000 | 44398000 | 43475000 | 42583000 |
Diluted Shares Outstanding | 46047000 | 45212000 | 44398000 | 43475000 | 42583000 |
Income Statement Trend
Omnicell Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 369.2M | 468.0M | 330.4M | 349.1M | 485.9M |
Short-term Investments | 12.5M | 11.9M | 11.5M | 10.7M | 10.2M |
Accounts Receivable | 256.4M | 252.0M | 299.5M | 240.9M | 190.1M |
Inventory | 88.7M | 110.1M | 147.5M | 119.9M | 96.3M |
Other Current Assets | 13.6M | 7.7M | 7.5M | 10.6M | 2.5M |
Total Current Assets | 815.5M | 927.6M | 881.8M | 780.7M | 829.4M |
Non-Current Assets | |||||
Property, Plant & Equipment | 125.3M | 121.0M | 129.4M | 137.8M | 136.1M |
Goodwill | 1.7B | 1.7B | 1.8B | 1.9B | 1.3B |
Intangible Assets | 246.7M | 277.8M | 323.7M | 374.6M | 262.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 78.3M | 56.7M | 46.6M | 46.4M | 40.3M |
Total Non-Current Assets | 1.3B | 1.3B | 1.3B | 1.4B | 995.1M |
Total Assets | 2.1B | 2.2B | 2.2B | 2.1B | 1.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 51.8M | 45.0M | 63.4M | 71.5M | 40.3M |
Short-term Debt | 185.0M | 10.5M | 10.8M | 501.1M | 12.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 595.7M | 367.8M | 428.4M | 876.2M | 276.4M |
Non-Current Liabilities | |||||
Long-term Debt | 197.5M | 603.6M | 606.0M | 39.9M | 516.1M |
Deferred Tax Liabilities | 1.1M | 1.6M | 2.1M | 51.7M | 39.6M |
Other Non-Current Liabilities | 7.2M | 6.3M | 6.7M | 7.8M | 19.2M |
Total Non-Current Liabilities | 282.0M | 670.1M | 652.2M | 119.6M | 580.6M |
Total Liabilities | 877.6M | 1.0B | 1.1B | 995.8M | 857.0M |
Equity | |||||
Common Stock | 57.0K | 56.0K | 55.0K | 54.0K | 53.0K |
Retained Earnings | 382.9M | 370.4M | 390.7M | 368.6M | 290.7M |
Treasury Stock | 290.3M | 290.3M | 290.3M | 238.1M | 238.1M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.2B | 1.2B | 1.1B | 1.1B | 967.5M |
Key Metrics | |||||
Total Debt | 382.5M | 614.1M | 616.7M | 541.0M | 528.3M |
Working Capital | 219.8M | 559.8M | 453.4M | -95.5M | 553.0M |
Balance Sheet Composition
Omnicell Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 12.5M | -20.4M | 5.6M | 77.8M | 32.2M |
Depreciation & Amortization | 89.8M | 95.6M | 99.2M | 84.9M | 71.6M |
Stock-Based Compensation | 39.3M | 55.3M | 68.2M | 53.2M | 44.7M |
Working Capital Changes | 38.1M | 67.3M | -92.2M | -38.0M | 43.1M |
Operating Cash Flow | 168.6M | 191.1M | 47.7M | 196.8M | 191.4M |
Investing Activities | |||||
Capital Expenditures | -36.5M | -41.5M | -47.5M | -29.0M | -22.8M |
Acquisitions | 0 | 0 | 2.1M | -354.2M | -225.0M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -36.5M | -41.5M | -45.5M | -383.1M | -247.8M |
Financing Activities | |||||
Share Repurchases | 0 | 0 | -52.2M | 0 | -53.0M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 166.3M | - | 0 | 0 | 559.7M |
Debt Repayment | -391.7M | - | 0 | 0 | -200.0M |
Financing Cash Flow | -274.2M | 204.0K | -61.1M | -20.0M | 150.7M |
Free Cash Flow | 134.9M | 126.1M | 17.0M | 173.5M | 131.0M |
Net Change in Cash | -142.0M | 149.8M | -58.9M | -206.4M | 94.2M |
Cash Flow Trend
Omnicell Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
66.90
Forward P/E
17.84
Price to Book
1.18
Price to Sales
1.32
PEG Ratio
1.34
Profitability Ratios
Profit Margin
2.01%
Operating Margin
2.80%
Return on Equity
1.87%
Return on Assets
0.49%
Financial Health
Current Ratio
1.42
Debt to Equity
30.42
Beta
0.82
Per Share Data
EPS (TTM)
$0.48
Book Value per Share
$27.22
Revenue per Share
$24.74
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
omcl | 1.5B | 66.90 | 1.18 | 1.87% | 2.01% | 30.42 |
Veeva Systems | 44.1B | 55.52 | 6.66 | 13.70% | 27.29% | 1.29 |
Ge Healthcare | 34.6B | 14.83 | 3.40 | 25.80% | 11.22% | 107.67 |
10x Genomics | 1.7B | -9.18 | 2.18 | -11.30% | -13.13% | 11.22 |
Certara | 1.7B | 210.40 | 1.58 | 0.75% | 1.97% | 29.00 |
Phreesia | 1.4B | - | 5.34 | -22.67% | -13.94% | 2.60 |
Financial data is updated regularly. All figures are in the company's reporting currency.